Skip to content
ClinCalc Pro
Menu
Long-acting reversible contraception (Cu-IUD)

Intra-uterine contraceptive device (copper)

Brand names: TT380 Slimline, T-Safe, Mini TT380

A long-acting reversible, non-hormonal contraceptive device inserted into the uterine cavity, also used as emergency contraception.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Released copper ions are toxic to sperm and ova and provoke a sterile inflammatory endometrial reaction, preventing fertilisation and implantation.

Prescribing in practice

  • Exclude existing pregnancy and current pelvic infection before insertion, and counsel that the device offers no protection against sexually transmitted infections.
  • It is the most effective form of emergency contraception and can be used as ongoing contraception thereafter when fitted within the recommended window.
  • Avoid in unexplained vaginal bleeding, distorted uterine cavity, current pelvic inflammatory disease, and known copper allergy or Wilson's disease.

Monitoring

Review after the first menses or a few weeks post-insertion to check threads and exclude expulsion or infection, then as clinically indicated.

Counselling the patient

  • Periods may become heavier, longer or more painful, particularly in the early months.
  • Check the threads periodically and seek review if you cannot feel them or feel the hard plastic of the device.
  • Seek urgent care for severe pelvic pain, fever, or abnormal discharge, and remember it does not protect against STIs.

Evidence & guidelines

The copper intrauterine device is recognised by the FSRH as the most effective method of emergency contraception and a highly effective long-acting reversible contraceptive.

Reference: FSRH guidance; NICE CG30; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.